Related Experiment Video
Updated: Jan 8, 2026

The Rodent Model of Nonarteritic Anterior Ischemic Optic Neuropathy rNAION
Published on: November 20, 2016
Should Patients Who Develop Nonarteritic Anterior Ischemic Optic Neuropathy While Using PDE-5 Inhibitors Continue
Howard D Pomeranz1, Ore-Ofe O Adesina, Andrew G Lee
1Department of Ophthalmology (HP), Northwell Health, Great Neck, New York; The Ruiz Department of Ophthalmology and Visual Science (O-OA), McGovern Medical School at UTHealth Houston, Houston, Texas; Blanton Eye Institute (AGL), Houston Methodist Hospital, Houston, Texas; and Department of Ophthalmology and Visual Sciences (GPVS), Washington University in St. Louis, St. Louis, Missouri.
No abstract available in PubMed .
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Glaucoma: Overview
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Vasodilators

